ArticleJournal of molecular neuroscience : MN2025
CD73 Molecule Inhibitor Upregulates miR16 Expression in Experimental Glioblastoma and Inhibits Angiogenesis by Targeting VEGF.
Article in Journal of molecular neuroscience : MN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Oncogenic and Tumor-Suppressive Roles of SNHG18: A Double-Edged Long Noncoding RNA in Cancer.BioMed research international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The function of CD73 (Cluster of Differentiation 73), an enzyme involved in the formation of adenosine (ADO), in the development of glioblastomas has been demonstrated. Indeed, ADO helps tumor angiogenesis by stimulating endothelial cell migration, proliferation, and tube formation. However, the details of the molecular mechanisms are not yet fully understood. Given the importance of angiogenesis in cancer progression, invasion, and metastasis, this study aimed to investigate how the inhibition of CD73 by adenosine-5'-(α, β-methylene) diphosphate (APCP) affects the angiogenesis process of experimental orthotopic glioblastoma at mRNAs, microRNAs, and protein levels. According to the real-time-polymerase chain reaction (RT-PCR) results, inhibition of CD73 decreased the angiogenesis of glioblastoma by reducing the expression of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1-alpha (HIF-1α) by ****P < 0.0001 and **P < 0.01, respectively. Furthermore, immunohistochemical staining showed that this treatment protocol attenuated the expression of VEGF and CD31. Moreover, APCP treatment significantly increased miR-16 expression in glioblastoma model rats by P < 0.001, but no significant change in miR-29A expression was observed. The results showed that the treatment did not lead to systemic damage or significant weight loss. Our results suggest that inhibition of CD73 may reduce the formation of new tumor vessels by inhibiting the VEGF, HIF-1α, and CD31 in this process. Therefore, CD73 may be a practical target and provide new opportunities to improve the treatment of malignant brain tumors.
Indexed as
Identifiers
40140182What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.